Folic acid conjugated poly(amidoamine) dendrimer as a smart nanocarriers for tracing, imaging, and treating cancers over-expressing folate receptors

Fatima, Mahak; Sheikh, Afsana; Hasan, Nazeer; Sahebkar, Amirhossein; Riadi, Yassine; Kesharwani, Prashant

doi:10.1016/j.eurpolymj.2022.111156

Cited by 46 publications

(21 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When the receptors and ligands are bound, the number of free target receptors is limited. Subsequently, the nanoparticles compete to occupy the unbound target receptors [44,45]. This competition interferes with the transport of the nanoparticles into the cytoplasm.…”

Section: Competitive Cellular Uptakementioning

confidence: 99%

Simultaneous delivery of docetaxel and tariquidar to chemoresistance cancer cells using functionalized lipid nanocarriers

Kim

Lee

Choi

et al. 2022

Preprint

View full text Add to dashboard Cite

Background The simultaneous administration of tariquidar (TRQ) with docetaxel (DTX) using a nanostructured lipid carrier (NLC) functionalized with PEG (5mol%) and RIPL peptide (PRN) was constructed to overcome the multidrug resistance caused by DTX administration alone. Results Either DTX or TRQ loaded PRN (D-PRN or T-PRN) and both DTX and TRQ loaded PRN (D/T-PRN) were prepared using the solvent emulsification evaporation technique. NLC samples showed homogeneous spherical morphology with nano-sized dispersion (< 220 nm) and ZP values from − 15 mV to − 7 mV. DTX and/or TRQ was successfully encapsulated in NLC samples (> 95% EE and 73–78 µg/mg DL. In vitro cytotoxicity was concentration-dependent, and D/T-PRN exhibited the highest MDR reversal efficiency with the lowest combination index value. D/T-PRN increased the apoptotic cell death in MCF7/ADR cells by inducing cell cycle arrest in the G2/M phase. In a competitive cellular uptake assay, the single nanocarrier system exhibited better intracellular delivery efficiency of multiple probes to target cells compared to dual nanocarrier system. In the MCF7/ADR-xenografted mouse models, co-delivery with D/T-PRN significantly suppressed tumor growth compared to the other treatments. Conclusions Co-delivery of DTX/TRQ (1:1, w/w) using PRN will be a promising strategy against drug-resistant breast cancer cells.

show abstract

Section: Competitive Cellular Uptakementioning

confidence: 99%

Simultaneous delivery of docetaxel and tariquidar to chemoresistance cancer cells using functionalized lipid nanocarriers

Kim

Lee

Choi

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Nowadays a maximum number of drug targeting methods are based on nano-formulations because targeting therapy becomes easier when given in the form of a nano-formulation. [7][8][9][10][11][12][13][14][15][16] In the category of nano-formulations nanobers have vast application in the eld of medicines, [17][18][19][19][20][21][22][23][24][25] and amongst the nanobers the magnetic nanobers have different applications due to their characteristics and magnetic memory, as well as environmental treatment, catalysts, and biomedicine. 26,27 Nanobers can be simply dened as the bers of the polymers having the size in the range of nanometer where the temperature of calcination and holding time affects the shape, diameter, ber morphology, and crystallite size of the nanober structure.…”

Section: Introductionmentioning

confidence: 99%

“…Nowadays a maximum number of drug targeting methods are based on nano-formulations because targeting therapy becomes easier when given in the form of a nano-formulation. 7–16 In the category of nano-formulations nanofibers have vast application in the field of medicines, 17–19,19–25 and amongst the nanofibers the magnetic nanofibers have different applications due to their characteristics and magnetic memory, as well as environmental treatment, catalysts, and biomedicine. 26,27…”

Section: Introductionmentioning

confidence: 99%

Recent update on electrospinning and electrospun nanofibers: current trends and their applications

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Immuno-oncology is the newest field of research in this area and its scope and full potential are yet to be explored. As part of immunotherapy, specific parts of the patient’s immune system are used to treat a range of diseases, including cancer and mostly solid tumors [ 2 , 3 , 4 , 5 , 6 , 7 , 8 ]. Cancer immunotherapy aims to re-activate the immune system, which has been suppressed by tumor cells in numerous ways.…”

Section: Introductionmentioning

confidence: 99%

Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment

et al. 2022

Self Cite

View full text Add to dashboard Cite

Immunotherapy is one of the four pillars of cancer treatment that has recently emerged as a beacon of hope for cancer patients. Certain immunotherapies, for example, immune checkpoint inhibitor therapy, monoclonal antibody therapy and chimeric antigen T-cell therapy have garnered extensive interest in response to their exceptional properties that activate the immune system to respond to cancer cells, inhibiting their progression. In the era of rapid development, dostarlimab, an anti-programmed cell death protein (PD-1) monoclonal antibody has mesmerized the medical profession by showing complete (100%) cure of patients with colorectal cancer. Not only this, the results obtained from clinical trials revealed no major side effects in any of the participants in the study. Dostarlimab has also shown promising results in endometrial cancer, ovarian cancer, melanoma, head and neck cancer, and breast cancer therapy. This review focuses upon the action of immunotherapy, extensively emphasizing the miraculous therapy to activate T-cells for cancer treatment. Based on this, we discuss major ongoing clinical trials and combination immunotherapies to enlighten future clinicians and researchers about the response of dostarlimab against various cancers.

show abstract

Folic acid conjugated poly(amidoamine) dendrimer as a smart nanocarriers for tracing, imaging, and treating cancers over-expressing folate receptors

Cited by 46 publications

References 114 publications

Simultaneous delivery of docetaxel and tariquidar to chemoresistance cancer cells using functionalized lipid nanocarriers

Simultaneous delivery of docetaxel and tariquidar to chemoresistance cancer cells using functionalized lipid nanocarriers

Recent update on electrospinning and electrospun nanofibers: current trends and their applications

Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment

Contact Info

Product

Resources

About